Your Sorted CME/CE Activities

Conversations in PAH: Global Trends in PH Clinical Trials and Risk Assessment
This AMA/ANCC/ACPE activity features a recorded discussion among three leading pulmonary hypertension (PH) experts and is designed to keep healthcare professionals on top of the most recent clinical findings.

New information is constantly being learned about the management of patients with PH. Pulmonary Hypertension Due to Interstitial Lung Disease (PH-ILD) represents a complex condition which now has a recently approved inhaled therapy to improve exercise ability. Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but treatable complication of PE, which is often indistinguishable from pulmonary arterial hypertension (PAH). All patients with PH benefit from intensive, continuous clinical monitoring either in person or remotely to guide escalation of treatments. PH remains a disease with poor outcomes, necessitating early diagnosis and appropriate intervention. Improvements in survival and care depends on improving clinician awareness of the latest research and perspectives. This activity brings cutting-edge research to busy clinicians enabling them to readily keep abreast of emerging published research as it relates to the management of PH.
Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.

Ronald Oudiz, MD Ronald Oudiz, MD, FACP, FACC, FCCP
Professor of Medicine
David Geffen School of Medicine at UCLA
Interim Chief, Division of Cardiology
Director, Liu Center for Pulmonary Hypertension
Ludquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Expert Faculty:
Steven Nathan, MD Steven Nathan, MD
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Nick H. Kim, MD Nick H. Kim, MD
Professor of Medicine
Medical Director, Pulmonary Thromboendarterectomy Program
Division of Pulmonary, Critical Care and Sleep Medicine
University of California, San Diego

Supported by independent educational grants from United Therapeutics Corporation, Bayer U.S. and Actelion Pharmaceuticals U.S., Inc., A Janssen Pharmaceutical Company of Johnson & Johnson

Launch Date: August 4, 2022
Release Date: July 18, 2022
Expiration Date: June 30, 2023

June 30, 2023
Mini Module